6-Thioguanine resistant peripheral blood lymphocytes in humans following psoralen, long-wave ultraviolet light (PUVA) therapy.
A recently described method that enumerates variant 6-thioguanine resistant peripheral blood lymphocytes present in vivo in man as a potential marker of somatic cell mutations occurring in vivo was used to study 18 psoriatic patients receiving PUVA therapy, 16 conventinally treated psoriatic patients, 10 vitiligo patients receiving PUVA therapy and 7 untreated individuals with vitiligo. Variant lymphocyte frequencies determined for these individuals were compared with those determined for groups of 10 concurrent and 63 cumulative healthy control individuals. Variant frequencies were elevated in psoriatic and vitiligo patients receiving PUVA therapy and in conventionally-treated psoriatic patients. They were not elevated over control values in untreated vitiligo patients.
D000328:Adult; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008214:Lymphocytes / Q000187:drug effects*; D008297:Male; D008730:Methoxsalen / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D009154:Mutation; D010778:Photochemotherapy / Q000009:adverse effects*; D011565:Psoriasis / Q000097:blood / Q000188:drug therapy; D013866:Thioguanine / Q000494:pharmacology*; D014466:Ultraviolet Rays; D014820:Vitiligo / Q000097:blood / Q000188:drug therapy
D013866:Thioguanine; D008730:Methoxsalen